Arvinas shows strong ESR1-mutant data with limited scope, niche SERD competition, Pfizer uncertainty, and a high-risk pipeline. See why ARVN stock is a hold.
Organigram stands out for its strong balance sheet and strategic partnership with BTI. Read why OGI is upgraded to Buy and VFF is downgraded to Strong Sell.
Amazon S3 on MSN
Apple's Secret Store — MAJOR Savings!
OFF iPhones, Macbooks and more! Subscribe: <a href=" For more money-saving tips, check out our full playlist: • Rossen ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈